

Media Release

Changes in the Board of Directors

Altstätten, January 9, 2013 – COLTENE Holding AG (SIX Swiss Exchange: CLTN), an internationally leading developer and producer of dental consumables, announces today that its Board of Directors nominates Prof. Dr. med. dent. Roland Weiger as a new Board member for election at the next ordinary Annual General Meeting in April 2013. Prof. Roland Weiger is currently serving as Professor and Director of the Periodontology, Endodontology and Cariology Clinic at the University of Basel and Director of its Department of Dental Medicine. The Board of Directors also announces that Jerry Sullivan, former CEO and current Board Member of COLTENE, will not seek re-election at the end of his current period of office in April 2013.

“I would like to sincerely thank Jerry Sullivan for his many years of valuable contributions to COLTENE, as a member of management, as CEO and in recent years as a Board Member. His profound knowledge of the dental market and the COLTENE organisation has been of great benefit to COLTENE during his 30 years of service with the Company,” says Nick Huber, Chairman of the Board of Directors of COLTENE Holding AG. “And I am very happy to propose Prof. Roland Weiger as a new member to the Board of Directors. His profound knowledge of dental procedures and special expertise in the area of restorative dentistry will bring a high level of expertise to COLTENE’s Board of Directors in a core area of the Company.”

Prof. Roland Weiger (born in 1961 in Reutlingen, Germany) studied dentistry at the Eberhard-Karls University in Tübingen, graduating summa cum laude in 1987. He started his career in the Polyclinic for Dentistry in the Tooth, Mouth and Jaw Centre at the University Clinic, Tübingen, where he became a Consultant Dental Surgeon in 1996 and then Professor of Dentistry in Endodontology in 2000. In 2002 he was elected to his current position at the University of Basel, a position which combines teaching, research and patient treatment work. Prof. Weiger was Chairman of the Research Committee, European Society of Endodontology (ESE) until 2012 and is currently President of the Expert Commission of the Swiss Organisation for Preventative and Restorative medicine (SVPR), a member of the Boards of the Swiss Society of Periodontology (SSP) and the German Society for Endodontology and Dental Traumatology (DGET), member of the Research Fund of the Society of Swiss Dentists (SSO) and President of the Finance Committee of the Department of Dental Medicine, University Basel.

The Board of Directors is confident that in proposing Prof. Roland Weiger as a future Board Member to shareholders, it is proposing a person who will bring a deep understanding of current dental methodology and practices and future trends to the Company’s governing body.

Sign-up for e-mail subscription is available at <http://www.coltene.com/10225/Newsletter.html>

For further information: Michael Düringer, Corporate Communications/Investor Relations, phone +41 43 244 81 42, mobile +41 79 653 19 75, e-mail michael.dueringer@coltene.com

Financial Calendar

Full-year Results 2012	New date: March 8, 2013
Annual General Meeting of Shareholders	New date: April 15, 2013
Half-year Report 2013	August 15, 2013

About COLTENE

COLTENE is an internationally leading developer, manufacturer and seller of dental consumables and small equipment. COLTENE has state-of-the-art production facilities in the USA, Switzerland, Germany, Hungary and Brazil. Dentists and dental labs use COLTENE products for traditional as well as implant-based therapies and dental reconstructions. The registered shares of COLTENE Holding AG (CLTN) are listed on SIX Swiss Exchange. Learn more about COLTENE and our products at www.coltene.com.

This press release and oral statements or other written statements made, or to be made, by us contain forward-looking statements that do not relate solely to historical or current facts. These forward-looking statements are based on the current plans and expectations of our management and are subject to a number of uncertainties and risks that could significantly affect our current plans and expectations, as well as future results of operations and financial condition. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.